Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Our focus is on ensuring rights are clearly defined, value is appropriately allocated, and technology and IP assets can be confidently shared, scaled, and monetised across markets. We advise on a broad range of licensing models and transfer strategies, tailoring frameworks to reflect the nature of the underlying technology, ownership position, and commercial objectives.
By collaborating closely with colleagues in our corporate, M&A, finance, tax, privacy, antitrust, and regulatory practices, we deliver integrated solutions to even the most complex arrangements. Whether you're a fast-growing start-up or a global market leader, we meet you where you need us most – with clarity, confidence, and a focus on your goals.
Our capabilities at a glance
400
+
IP lawyers and professionals
90
+
IP & technology transactions lawyers
50
%+
we represent more than half of the world's best 100 global brands, 2024 Interbrand Report
Key contacts
Representative experience
Representing Daiichi Sankyo in its out-license of three DXD anti-body drug conjugates.
Acting for a Japanese engineering company in relation to its licensing negotiations with a European university in respect of joint research, development and exploitation.
Advised Ford on the IP aspects of its sale of Volvo Cars to Zhejiang Geely and its sale of Jaquar and Land Rover to Tata Motors, including on complex post-sale cross-licensing arrangements.
Advised Recordati on the licensing and supply agreements with Amarin for the commercialization of the cardiovascular drug Vazkepa® in 59 countries.
Represented a leading manufacturer and retailer of women’s intimate apparel, on a range of manufacturing, distribution and licensing matters.
Represented Gilead Sciences in its agreement with Dragonfly to obtain development and commercialization rights in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.
Represented Quorum Business Solutions in connection with its commercial arrangements, including direct software licensing, cloud, and software as service arrangements.
Represented SymBio Pharmaceuticals on various licensing arrangements with counterparties in the U.S. and in Europe.
Represented Tmunity Therapeutics, a clinical stage biotherapeutics company focused on next-generation T cell immunotherapy, on licensing and due diligence.
Representing Morphosys Ag in the drafting and negotiating of an agreement regarding the co-development and co-marketing as well as the out-licensing (ex-U.S.) of its blood cancer product.
Advising HTC on the then largest patent litigation before the European courts. Multijurisdictional cases against Nokia and NPEs, and advising on FRAND licensing terms.
Advising a leading Japanese pharmaceutical firm on multiple Hatch-Waxman lawsuits relating to the client's blockbuster product.
Successfully representing Ashland in a landmark patent and trade secret infringement dispute against a Chinese company.
Advising Merck & Co., Inc. (Kenilworth, New Jersey, USA) in a trademark, domain name, and social media dispute with Merck KGaA. over use of the name “Merck” in Europe and U.S.
Awards and recognitions
Europe IP Transactions & Advisory Law Firm of the Year (Shortlist)
Managing IP EMEA Awards
2026
IP Transactions & Advisory Law Firm of the Year – Germany & Netherlands (Shortlist)
Managing IP EMEA Awards
2026
Firm of the Year IP Transactions - US (Shortlist)
Managing IP Americas Awards
2025
Americas Impact Deal of the Year
Managing IP Americas
2024
